ORIC Pharmaceuticals Conference Call Summary Company Overview - **Company**: ORIC Pharmaceuticals (NasdaqGS:ORIC) - **Focus**: Development of rinzimetostat, a PRC2 inhibitor for prostate cancer, and enozertinib, an EGFR inhibitor for non-small cell lung cancer, in collaboration with Bayer and Johnson & Johnson [4][6] Key Points and Arguments Clinical Data and Pipeline - **Rinzimetostat**: A next-generation PRC2 inhibitor designed for superior potency and a 20-hour clinical half-life, minimizing toxicity [5] - **Phase III Trial**: The first phase III trial, named Himalayas-1, will target post-abiraterone metastatic CRPC, a market worth $3.5 billion annually in the U.S. [6][10] - **Efficacy**: Rinzimetostat shows competitive efficacy with early landmark radiographic progression-free survival (RPFS) rates and a favorable safety profile compared to existing therapies [5][8][10] Competitive Landscape - **Current Therapies**: Existing treatments like enzalutamide and docetaxel show median RPFS of 6-9 months, while rinzimetostat aims for a double-digit RPFS [6][7] - **Comparison with Meverometostat**: Rinzimetostat's early data suggests it may outperform meverometostat in terms of safety and efficacy, with a cleaner safety profile [7][9][36] Safety Profile - **Adverse Events**: Most adverse events for rinzimetostat in combination with darolutamide are grade 1 or 2, with a significantly lower incidence of severe events compared to competitors [9][25][36] - **Patient Population**: The trial population is more heavily pretreated than competitors, with a median baseline PSA of 26 for the 400 mg dose group, indicating a more advanced disease state [24][72] Market Potential - **Addressable Market**: The U.S. market for post-abiraterone mCRPC is estimated at over $3.5 billion, with potential expansion into other prostate cancer indications, increasing the total market to over $10 billion [10][41] - **Physician Insights**: Market research indicates a strong preference for rinzimetostat due to its safety profile, potentially capturing 80% of the PRC2 class market share [49] Future Development - **Additional Trials**: Plans for future phase III trials in other indications, including metastatic castration-sensitive prostate cancer and colorectal cancer, are underway [42][50] - **FDA Engagement**: Regular communication with the FDA is ongoing, with an end-of-phase I meeting planned to finalize the trial design and RP3D selection [65][66] Other Important Content - **Preclinical Data**: Rinzimetostat has shown superior potency in preclinical studies compared to first-generation PRC2 inhibitors, supporting its potential as a best-in-class therapy [11][12] - **Mechanistic Rationale**: The drug's ability to reverse epigenetic reprogramming in prostate cancer cells enhances its therapeutic potential when combined with AR inhibitors [14][15] This summary encapsulates the critical insights from the ORIC Pharmaceuticals conference call, highlighting the company's strategic focus on rinzimetostat and its promising clinical data, competitive positioning, and market potential.

Group 1: Cancer Research Developments - Johnson & Johnson reported promising Phase 1b data for pasritamig, a bispecific T-cell engager combined with docetaxel for metastatic castration-resistant prostate cancer, showing no unexpected safety concerns and durable reductions in prostate-specific antigen (PSA) [1][2] - The combination of pasritamig with docetaxel provides a strong foundation for Phase 3 development, addressing previous shortcomings in the field [2] Group 2: New Drug Application - Johnson & Johnson submitted a supplemental Biologics License Application to the U.S. FDA for IMAAVY® (nipocalimab-aahu), which, if approved, would be the first treatment for warm autoimmune hemolytic anemia (wAIHA) [3] - Phase 2/3 ENERGY trial data indicated a rapid, durable hemoglobin response and significant improvement in fatigue for patients treated with IMAAVY® [3] Group 3: Company Overview - Johnson & Johnson, founded in 1886, is a global multinational pharmaceutical, biotechnology, and medical technologies company, operating through two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices) [4]

Core Insights - The article discusses preliminary results from a Phase 1b study of pasritamig (JNJ-78278343), a bispecific T-cell engaging antibody, in combination with docetaxel for treating metastatic castration-resistant prostate cancer [1] Group 1: Study Results - The combination therapy demonstrated deep prostate-specific antigen (PSA) responses, indicating its potential effectiveness in treating the disease [1] - The safety profile of the treatment was reported as favorable, suggesting a manageable side effect profile for patients [1] Group 2: Future Plans - Johnson & Johnson plans to advance the therapy into Phase 3 clinical trials, indicating confidence in the drug's potential [1] - The study highlights the potential of this first-in-class therapy to expand the role of immunotherapy in prostate cancer treatment [1]

Core Viewpoint - OSE Immunotherapeutics and the FoRT Foundation have completed patient enrollment in the Combi-TED Phase 2 clinical trial, which evaluates the therapeutic cancer vaccine Tedopi® in combination with nivolumab or docetaxel for patients with Non-Small Cell Lung Cancer (NSCLC) [1][4][8] Group 1: Clinical Trial Details - The Combi-TED trial is an open-label, randomized, three-arm Phase 2 study involving 105 HLA-A2 positive patients with metastatic NSCLC who have not shown evidence of EGFR mutations or ALK or ROS1 rearrangement after first-line treatment [3][8] - The primary endpoint of the trial is the 1-year survival rate, with results expected in the second half of 2026 [3][8] - The trial is sponsored by the FoRT Foundation and conducted across sites in Italy, France, and Spain [2] Group 2: Expert Commentary - Dr. Federico Cappuzzo, Chief Investigator, expressed optimism about the trial's completion, highlighting the potential of Tedopi® to enhance the effectiveness of checkpoint inhibitors or chemotherapy [4] - Silvia Comis, Chief Clinical and Medical Research Officer, noted that the trial represents a significant step in evaluating innovative second-line treatment combinations for NSCLC [5] Group 3: Company Background - OSE Immunotherapeutics is focused on developing first-in-class therapies in immuno-oncology and immuno-inflammation, aiming to address unmet patient needs [6] - The company collaborates with leading academic institutions and biopharmaceutical companies to develop transformative medicines for serious diseases [6]

Group 1: Financial Performance - CSPC reported total revenue of RMB13.3 billion in 1H25, with core revenue at RMB12.2 billion, down 25% YoY and 4% HoH, representing 44% of the prior FY25 estimate [1] - In 2Q25, core revenue declined by 6% QoQ and 22% YoY, primarily due to softness in NBP sales and volume-based procurement impacts [1] - Attributable net profit reached RMB2.5 billion, representing 45% of the previous full-year FY25 forecast [1] Group 2: Business Development (BD) Opportunities - CSPC has secured six out-licensing deals since late 2024, with a recent deal involving an AI-powered small molecule discovery platform licensed to AstraZeneca valued over US$5 billion [2] - Management anticipates two additional large-scale BD deals in 2H25, each expected to exceed US$5 billion, including an EGFR ADC and a platform-based out-licensing [2] - CSPC has a robust pipeline of 40-50 assets with BD potential, including high-profile candidates like EGFR ADC and PD-1/IL-15 bsAb [2] Group 3: Product Development and Clinical Trials - SYS6010, an EGFR ADC, is in global Phase 3 development with pivotal studies ongoing in China for NSCLC [3] - CSPC plans to achieve First Patient In (FPI) for two Phase 3 trials in 2H25 in the US, comparing SYS6010 to docetaxel in EGFR wild-type NSCLC [3] - SYS6010 mono has shown an encouraging median progression-free survival of 7.6 months in EGFR-mutant NSCLC patients post-TKI and chemotherapy [3] Group 4: Investment Outlook - CSPC's BD deals are expected to be a key sustainable driver of earnings growth, leading to a revision of the target price from HK$10.08 to HK$12.11 [4]

Core Insights - NuCana plc has initiated the dosing of the first patients in the expansion study of NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant melanoma, with initial data expected in Q4 2025 and final data in 2026 [1][2] - The company reported a net loss of £24.1 million for Q2 2025, which includes a significant loss on revaluation of warrants, compared to a net loss of £7.0 million in Q2 2024 [7][11] - NuCana's cash and cash equivalents increased to £8.4 million as of June 30, 2025, up from £4.0 million at the end of Q1 2025, with additional funds raised through an ATM offering expected to extend the cash runway into 2029 [4][6] Clinical Development - NUC-7738 is designed to impact gene expression in cancer cells and has shown a favorable safety profile, meaningful tumor volume reduction, and prolonged progression-free survival in patients with PD-1 inhibitor refractory metastatic melanoma [2] - NUC-3373, another lead program, is a targeted thymidylate synthase inhibitor with immune-modulating properties, currently in a Phase 1b/2 study, showing notable tumor volume reductions and prolonged progression-free survival in patients with advanced solid tumors [2][5] Financial Position - As of June 30, 2025, NuCana's total assets were £16.2 million, with total equity attributable to equity holders amounting to £7.4 million [12][13] - The company has raised gross proceeds of £38.4 million in 2025 through various financing initiatives, positioning it well for upcoming clinical milestones [2][6] Anticipated Milestones - Initial data from the Phase 1/2 expansion study of NUC-7738 is expected in 2025, with regulatory guidance from the FDA anticipated in 2026 [5] - Additional data from the ongoing Phase 1b/2 study of NUC-3373 is also expected to be announced later in 2025 [5]

Core Viewpoint - The FDA and EMA have authorized a confirmatory Phase 3 trial for masitinib in metastatic castrate-resistant prostate cancer (mCRPC), utilizing a biomarker-driven patient selection approach to target those most likely to benefit from the treatment [1][2]. Study Design - Study AB22007 is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial designed to confirm the efficacy and safety of masitinib in combination with docetaxel for mCRPC patients [3]. - The trial will enroll 600 patients, with a primary endpoint of radiographic progression-free survival (rPFS) and overall survival as the first secondary endpoint [4]. Medical Need - Masitinib is positioned to address a high unmet medical need in mCRPC patients who have relapsed after hormone treatments, as there are currently no registered drugs for use in combination with docetaxel in this patient population [5][6]. - Metastatic prostate cancer has a 5-year survival rate of approximately 30%, highlighting the critical need for effective treatments [7]. Patient Population - The estimated population of mCRPC patients eligible for chemotherapy is around 75,000 in the EU and 50,000 in the USA [8]. - The biomarker alkaline phosphatase (ALP) has been validated to predict the response to masitinib in mCRPC patients, indicating a potential new first-line treatment option [8]. Efficacy Results - The combination of masitinib and docetaxel showed a significant progression-free survival (PFS) benefit, with a hazard ratio of 0.79, indicating a 21% reduction in the risk of progression compared to control [10]. - A greater treatment effect was observed in patients with lower baseline ALP levels, with a 47% reduced risk of progression in those with ALP ≤ 100 IU/L [11]. Safety Profile - The safety profile of masitinib in combination with docetaxel was acceptable, with no new safety signals observed, marking a successful example of a Phase 3 trial that improved PFS [13]. Patent Protection - AB Science has filed a patent application for methods of treating mCRPC with masitinib, which has been granted by the European Patent Office, providing protection until 2042 for the treatment of mCRPC in patients with low metastatic involvement [14][15].

Core Insights - NuCana plc is advancing its clinical development programs for its lead anti-cancer medicines, NUC-7738 and NUC-3373, with a focus on key milestones towards commercialization [2][4][7] - The company has initiated an expansion study of NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant melanoma, with initial data expected in Q4 2025 and final data in 2026 [1][2] - Financial results for Q1 2025 show a net loss of £2.5 million, a significant reduction from £6.8 million in Q1 2024, indicating improved financial performance [6][10] Clinical Development Updates - NUC-7738 has shown a favorable safety profile and meaningful tumor volume reduction in patients with PD-1 inhibitor refractory metastatic melanoma, leading to the initiation of an expansion trial [2][4] - NUC-3373 is being evaluated in a Phase 1b/2 study in combination with pembrolizumab for advanced solid tumors and with docetaxel for lung cancer, with notable tumor volume reductions reported [2][4] - The company plans to meet with the U.S. FDA to discuss the regulatory strategy for NUC-7738 based on the promising results from ongoing studies [2][4] Financial Position - As of March 31, 2025, NuCana had cash and cash equivalents of £4.0 million, down from £6.7 million at the end of 2024, but has since raised an additional £8.8 million to extend its cash runway into Q4 2026 [4][5][6] - The company reported a basic and diluted loss per ordinary share of £0.02 for Q1 2025, compared to £0.13 for the same period in 2024, reflecting improved financial health [6][10] - Total assets decreased from £14.774 million at the end of 2024 to £11.601 million as of March 31, 2025, primarily due to cash outflows [11][12]